Context: Blood testosterone codetermines the threshold for erotosexual imagery and sexual activity. Androgen deprivation may therefore have a place in the treatment of unacceptable sexual behavior. Although androgen deprivation can be effective for sex offenders, their basic human rights must be respected; otherwise such treatment constitutes a violation of their physical integrity and is ethically unacceptable. As experience in treating prostate cancers demonstrates, androgen deprivation may have serious side effects. Endocrinologists are qualified to advise on and monitor androgen deprivation, but they are placed in an atypical position because the indication for such treatment is not dictated by endocrine disease.
Objective: The aim of this study was to provide an ethical framework for advising on androgen deprivation treatment of sex offenders and dealing with side effects.
Evidence Acquisition And Synthesis: A literature search was conducted in PubMed, Psychinfo, and references from the multiple systematic reviews and meta-analyses published on this topic. An attempt has been made to provide an appreciation of the ethical aspects of androgen deprivation in sex offenders, the efficacy of treatment, the potential risks of treatment, therapeutic options, and recommendations for monitoring treatment.
Conclusions: Provided that the human rights of sex offenders are respected and informed consent is given, androgen deprivation within a comprehensive framework of psychotherapeutic treatment can make a meaningful contribution to the prevention of recidivism by enabling better control of sexual impulses. Knowledge of side effects and their treatment has been mostly gleaned from experience with prostate cancer patients, and this should be made available to sex offenders undergoing androgen deprivation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/jc.2011-1540 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relationship Between Pre- and Post-Orchidectomy Serum Dihydrotestosterone and Prostate Cancer Severity in a Cohort of Nigerian Patients.
West Afr J Med
September 2024
Urology Department, Dorset County Hospital, Dorchester, UK.
Introduction: Prostate cancer (PCa) is the commonest urologic cancer worldwide and the leading cause of male cancer deaths in Nigeria. In Nigeria, orchidectomy remains the primary androgen deprivation therapy. Dihydrotestosterone (DHT) is the active prostatic androgen, but its relationship with PCa severity has not been extensively studied in Africa.
View Article and Find Full Text PDFSABR tolerance after prostatectomy: pushing the boundaries of ultrahypofractionation.
Clin Transl Oncol
January 2025
Department of Radiation Oncology, HM Hospitales, C/Oña 10, 28050, Madrid, Spain.
Objective: To evaluate the feasibility and tolerance of ultra-hypofractionated SABR (stereotactic ablative radiation therapy) protocol following radical prostatectomy.
Patients And Methods: We included patients undergoing adjuvant or salvage SABR between April 2019 and April 2023 targeting the surgical bed and pelvic lymph nodes up to a total dose of 36.25 Gy (7.
IL-1β in Neoplastic Disease and the Role of Its Tumor-Derived Form in the Progression and Treatment of Metastatic Prostate Cancer.
Cancers (Basel)
January 2025
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Since its discovery, IL-1β has taken center stage as a key mediator of a very broad spectrum of diseases revolving around immuno-mediated and inflammatory events. Predictably, the pleiotropic nature of this cytokine in human pathology has led to the development of targeted therapeutics with multiple treatment indications in the clinic. Following the accumulated findings of IL-1β's central modulatory role in the immune system and the implication of inflammatory pathways in cancer, the use of IL-1β antagonists was first proposed and then also pursued for oncology disorders.
View Article and Find Full Text PDFEarly Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature.
Cancers (Basel)
January 2025
Department of Radiation Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Background: The ideal timing of androgen deprivation therapy (ADT) for patients with biochemical recurrence (BCR) of prostate cancer (PCa) remains controversial due to its side effects and uncertain impact on survival outcomes.
Methods: We performed a review of the current literature by comprehensively searching the PubMed, Embase, and Cochrane databases to determine the optimal timing of ADT initiation after biochemical recurrence. We selected 26 studies including systematic reviews, randomized controlled trials (RCTs), and retrospective studies, while also reviewing practice guidelines.
An Updated Systematic Review and Network Meta-Analysis of First-Line Triplet vs. Doublet Therapies for Metastatic Hormone-Sensitive Prostate Cancer.
Cancers (Basel)
January 2025
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
: The addition of androgen receptor pathway inhibitors (ARPIs) to androgen deprivation therapy (ADT), with or without docetaxel (Doc), is currently recommended for metastatic, hormone-sensitive prostate cancer (mHSPC). Recently, the ARANOTE trial evaluated the efficacy and safety of Darolutamide + ADT in this setting. We aimed to update a network meta-analysis (NMA) of these combination therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!